NovaBlock Capital
NovaBlock Capital is a thesis-driven investment firm that focuses on digital assets, tokenized securities, and blockchain technology companies . We believe blockchain technology is poised to be one of the most disruptive technologies of the 21st century. Our mission is preserve and grow our limited partner's capital and drive development and widespread adoption of blockchain technology.
Novacap
Novacap is a private equity firm based in Montreal, Quebec, Canada, founded in 1981. The firm specializes in mid-market buyouts and has a strong track record of driving growth and creating long-term value for its portfolio companies. With over 40 years of experience, Novacap operates with a team of professionals dedicated to building world-class companies through a partnership approach.
Novacap focuses on sectors such as technology, digital infrastructure, and financial services. The firm manages over $16 billion in assets across various funds, including Novacap Industries V and Novacap Financial Services I. Novacap invests in companies primarily in North America, supporting them through different stages of growth with a patient and global approach.
Notable investments by Novacap include Syntax - a provider of comprehensive technology solutions, Master Group - a leader in HVAC-R distribution, InVita Healthcare Technologies - specializing in blood management solutions, Canada Diagnostic Centres - a network of medical imaging clinics, and Eddyfi Technologies - an industrial technology company.
Novalpina Capital LLP
Novalpina Capital LLP is a private equity firm based in London, United Kingdom, founded in 2017. The firm is led by a small team of five, including partners Timothy Lee and Bastian Lueken. Novalpina is known for its strategic investments and acquisitions, focusing on creating value through active management and operational improvements.
The firm primarily invests in the industrial and business services sectors, with a particular interest in companies that can benefit from strategic guidance and capital infusion. Novalpina typically engages in medium to large-sized investments, focusing on late-stage opportunities. While specific check sizes are not disclosed, the firm operates with a global investment mandate, seeking opportunities across various geographies.
One of Novalpina's notable investments includes the acquisition of NSO Group, a company specializing in internet security research and consulting. This acquisition highlights Novalpina's interest in technology and security sectors, aiming to leverage its expertise to drive growth and innovation within its portfolio companies.
Novartis Venture Fund
Novartis Venture Fund is a life science investor with bases in Basel, Switzerland, and Cambridge, Massachusetts. The fund focuses on fostering innovation and generating returns by investing in life science companies. With a team experienced in drug development, they take a hands-on approach to their investments, working closely with management to create clinical impact.
The fund invests in biotechnology and biopharmaceuticals at various stages of growth. They manage over USD 750 million in committed capital and have more than 40 portfolio companies across North America and Europe. Their investment strategy emphasizes developing novel therapeutics and platforms that address unmet patient needs in healthcare.
Notable investments include companies such as: Amgen - biotechnology leader, Alnylam Pharmaceuticals - RNA interference therapies, and Editas Medicine - gene editing technology. Other portfolio companies include: Zymeworks - therapeutic proteins, and Alector - immune-mediated diseases.
Novastar Ventures
Novastar Ventures is a venture capital investor headquartered in London, with additional offices in Nairobi and Lagos. Founded by Andrew Carruthers and Steve Beck, the firm assembles a diverse team across key entrepreneurial hubs in Africa and the UK. Novastar is committed to partnering with bold entrepreneurs that are transforming markets and sectors in Africa while creating meaningful social and environmental impact, evidenced by their strong emphasis on ESG principles.
The firm focuses on sectors including CleanTech, ClimateTech, HealthTech, and Education. They typically invest in early to growth-stage companies, supporting them with investment sizes ranging from $1-5 million. With their recently closed Africa People and Planet Fund III raising $147 million, Novastar Ventures reinforces their commitment to sustainable African growth. The firm primarily invests across Africa, leveraging their regional expertise and networks.
Notable investments from Novastar’s portfolio include GreenWheels - an electric mobility company, ARC Ride - an electric vehicle startup, and Rechaj - a company within their electric mobility investments. Their portfolio highlights their focus on companies that deliver substantial impact and advancement within their respective industries.
Novator Partners LLP
Novator specialises in investing in companies that have the potential to disrupt markets across telecommunications, health and media/technology sectors. Through its private capital, deep sector experience and strong track record, Novator creates consistent growth and returns from recognising uncommon market opportunities.
<br />
Geographically, Novator has built its track record identifying opportunities in underserved markets that other firms typically shy away from. Our approach is to back local management teams in building dynamic challenger brands, or to build new companies with our own teams, hand-picked for their operational excellence.
Novel Growth Partners
Novel Growth Partners is a revenue-based financing venture fund that provides flexible capital solutions to early-stage software companies. Novel provides companies up to $1M in growth capital and leverages the operational expertise of its founders and partners to provide tactical sales and marketing support to entrepreneurs via its proprietary Growth Bootcamp. Novel invests in entrepreneurs focused on growing revenue and building a near term profitable company. Unlike other growth capital, Novel does not take equity or require personal guarantees.
Novella Center for Entrepreneurship
Novella Center for Entrepreneurship is a nonprofit accelerator based in Baltimore, Maryland, founded in 2013 by Jeff Cherry. The center is named in honor of Cherry's mother, Joyce Novella Cherry, and focuses on economic empowerment for historically neglected communities. The team, led by Cherry, a seasoned entrepreneur and venture capitalist, is dedicated to fostering entrepreneurship through the Conscious Venture Lab, which emphasizes stakeholder theory and conscious capitalism.
The center invests in early-stage companies across sectors such as cybersecurity, biotechnology, technology infrastructure, hospitality, consumer products, 3D manufacturing, mobile, and gaming. It offers immersive support and customized content through its partnership with FounderTrac, aiming to prepare founders for investment. Novella Center manages the Novella Center Fund with an AUM of $15 million, launched in 2022.
Notable investments include MyMonitor - enterprise systems in healthcare, BM Diagnostics - diagnostic equipment, Healthier Forms - decision/risk analysis, Parish Tec - financial services, and GetSenti - business/productivity software. These investments reflect the center's commitment to supporting diverse founders and creating inclusive opportunities.
Novitas Holdings
Novitas Holdings is a technology-focused investment firm based in San Francisco, founded in 2026 by Manav Sevak, the former CEO of Memora Health. The firm is dedicated to combining funding with operational and strategic guidance, working closely with founders to provide mentorship on product development, go-to-market strategies, and operational scaling. Novitas Holdings seeks to partner with startups positioned to create meaningful impact within their industries through sustainable growth and founder-led businesses.
The firm focuses on companies solving significant industry challenges and aims to build products intended for long-term relevance. Its investment strategy includes early-stage investments and participation in acquisitions of technology businesses, enabling portfolio companies to accelerate development and expand their market reach. While specific fund sizes were not disclosed, Novitas Holdings plans to leverage its expertise and connections for the benefit of its portfolio.
Notable investments and partnerships are not yet available as the firm has recently launched. However, its founder, Manav Sevak, brings extensive experience from his previous role at Memora Health, where he led the development of a patient engagement platform that successfully integrated with Commure's healthcare solutions after Memora's acquisition.
Novo Holdings A/S
Novo Holdings A/S is a Danish investment company based in Hellerup, responsible for managing the assets and wealth of the Novo Nordisk Foundation. Founded in 1999, Novo Holdings is the main shareholder of Novo Nordisk and Novozymes, operating with a team that spans across Copenhagen, London, San Francisco, Boston, Singapore, Shanghai, and Mumbai. Its focus lies in delivering strong returns while promoting health and sustainability, making it distinct with its long-term perspective and value-driven investment approach. The firm employs a diverse team that is committed to high performance with respect and responsibility.
Novo Holdings invests primarily in life sciences, covering sectors including healthcare services, pharmaceuticals, biotechnology, and medical devices. They manage a broad portfolio of equities, bonds, and private equity investments with assets under management totalling DKK 694 billion (approximately EUR 93 billion as of 2025). The firm's geographic focus includes North America, Europe, and Asia, allowing them to support a global array of companies.
Some notable investments by Novo Holdings include Myricx Bio, which was acquired by Novartis, Hemab Therapeutics, which completed a successful Nasdaq IPO, and LimmaTech Biologics, which was acquired by Lilly. These investments reflect their strategy in the healthcare sector, emphasizing a commitment to companies that align with their values of health and sustainability.